CL2021003580A1 - Compuestos que comprenden un ligando de proteína de activación de fibroblastos y su uso - Google Patents

Compuestos que comprenden un ligando de proteína de activación de fibroblastos y su uso

Info

Publication number
CL2021003580A1
CL2021003580A1 CL2021003580A CL2021003580A CL2021003580A1 CL 2021003580 A1 CL2021003580 A1 CL 2021003580A1 CL 2021003580 A CL2021003580 A CL 2021003580A CL 2021003580 A CL2021003580 A CL 2021003580A CL 2021003580 A1 CL2021003580 A1 CL 2021003580A1
Authority
CL
Chile
Prior art keywords
compounds
activation protein
protein ligand
fibroblast activation
fibroblast
Prior art date
Application number
CL2021003580A
Other languages
English (en)
Inventor
Frank Osterkamp
Dirk Zboralski
Eberhard Schneider
Christian Haase
Matthias Paschke
Aileen Höhne
Jan Ungewiss
Christiane Smerling
Ulrich Reineke
Anne Bredenbeck
Original Assignee
3B Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP19000325.1A external-priority patent/EP3763726A1/en
Application filed by 3B Pharmaceuticals Gmbh filed Critical 3B Pharmaceuticals Gmbh
Publication of CL2021003580A1 publication Critical patent/CL2021003580A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se relaciona con compuestos que comprenden un ligando de proteína de activación de fibroblastos y su uso.
CL2021003580A 2019-07-08 2021-12-30 Compuestos que comprenden un ligando de proteína de activación de fibroblastos y su uso CL2021003580A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19000325.1A EP3763726A1 (en) 2019-07-08 2019-07-08 Compounds comprising a fibroblast activation protein ligand and use thereof
EP19198813 2019-09-20

Publications (1)

Publication Number Publication Date
CL2021003580A1 true CL2021003580A1 (es) 2022-08-05

Family

ID=71409439

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021003580A CL2021003580A1 (es) 2019-07-08 2021-12-30 Compuestos que comprenden un ligando de proteína de activación de fibroblastos y su uso

Country Status (12)

Country Link
US (1) US20220273831A1 (es)
EP (1) EP3997103A1 (es)
JP (1) JP2022541753A (es)
KR (1) KR20220032079A (es)
CN (1) CN114341159B (es)
AU (1) AU2020310538A1 (es)
BR (1) BR112022000122A2 (es)
CA (1) CA3145340A1 (es)
CL (1) CL2021003580A1 (es)
IL (1) IL289675A (es)
MX (1) MX2022000252A (es)
WO (1) WO2021005125A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023525082A (ja) 2020-05-07 2023-06-14 アンスティテュ・クリー 免疫抑制線維芽細胞集団のバイオマーカーとしてのａｎｔｘｒ１及び免疫療法に対する応答を予測するためのその使用
WO2022160338A1 (zh) * 2021-02-01 2022-08-04 五一一制药股份有限公司 成纤维细胞活化蛋白-α显像剂的放射性标记配体及其制备方法
EP4227300A4 (en) 2021-02-10 2024-04-24 Yantai Lannacheng Biotechnology Co Ltd ASTRIDGED EVANS BLUE MODIFIED FIBROBLAST ACTIVATION PROTEIN INHIBITOR, METHOD OF PREPARING THE SAME AND USE THEREOF
CN114369084B (zh) * 2021-02-10 2023-02-03 烟台蓝纳成生物技术有限公司 一种截短型伊文思蓝修饰的成纤维细胞活化蛋白抑制剂及其制备方法和应用
GB202109922D0 (en) 2021-07-09 2021-08-25 Blue Earth Diagnostics Ltd Radiotracers and therapeutics binding to fibroblast activation protein (fap)
WO2023152671A1 (en) 2022-02-09 2023-08-17 Novartis Ag Pharmaceutical compositions comprising a 225-actinium-labelled complex and a bismuth sequestering agent
EP4282439A1 (en) 2022-05-23 2023-11-29 Erasmus University Rotterdam Medical Center Radioisotope labeled sstr2-agonists with linkers
CN115304582B (zh) * 2022-07-20 2023-05-12 北京法伯新天医药科技有限公司 FAP-α特异性肿瘤诊断显像剂
EP4311557A1 (en) * 2022-07-26 2024-01-31 Oncomatryx Biopharma, S.L. Fap-targeted antibody-drug conjugates
WO2024052431A1 (en) * 2022-09-07 2024-03-14 3B Pharmaceuticals Gmbh Prostate specific membrane antigen (psma) ligands and use thereof
EP4342890A1 (en) 2022-09-21 2024-03-27 Erasmus University Rotterdam Medical Center Platform and scaffold for fap targeting agents

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ503359A (en) 1997-09-29 2002-02-01 Point Therapeutics Inc Method for proliferating haematopoietic cells in vitro in the absence of exogenous cytokines
EP0953639A1 (en) 1998-04-30 1999-11-03 Boehringer Ingelheim International GmbH FAPalpha-specific antibody with improved producibility
US6890904B1 (en) 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
AU2001256325A1 (en) 2000-03-17 2001-09-24 Boehringer Ingelheim Pharma Kg Human and humanized fap-alpha-specific antibodies
EP1452868A2 (en) * 2003-02-27 2004-09-01 Pepscan Systems B.V. Method for selecting a candidate drug compound
US7374898B2 (en) 2004-10-12 2008-05-20 The Research Foundation Of State University Of New York Peptide inhibitors against seprase
WO2006125227A2 (en) 2005-05-19 2006-11-23 Genentech, Inc. Fibroblast activation protein inhibitor compounds and methods
US8933201B2 (en) 2006-06-07 2015-01-13 The Board Of Regents Of The University Of Oklahoma Substrates and inhibitors of antiplasmin cleaving enzyme and fibroblast activation protein and methods of use
JP2010523477A (ja) 2007-03-20 2010-07-15 トラスティーズ オブ タフツ カレッジ 線維芽細胞活性化タンパク質の阻害剤、およびそれを使用する方法
WO2010036814A1 (en) 2008-09-25 2010-04-01 Molecular Insight Pharmaceuticals, Inc. Selective seprase inhibitors
WO2011040972A1 (en) 2009-10-02 2011-04-07 Ludwig Institute For Cancer Research Ltd. Anti-fibroblast activation protein antibodies and methods and uses thereof
BR112013003361B8 (pt) 2010-08-13 2022-01-25 Roche Glycart Ag Anticorpo, composição, conjugado de anticorpo,formulação farmacêutica e uso do anticorpo
WO2013107820A1 (en) 2012-01-17 2013-07-25 Universiteit Antwerpen Novel fap inhibitors
EP2740726A1 (en) * 2012-12-07 2014-06-11 3B Pharmaceuticals GmbH Neurotensin receptor ligands
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
GB201402006D0 (en) 2014-02-06 2014-03-26 Oncomatryx Biopharma S L Antibody-drug conjugates and immunotoxins
EP3154638A1 (en) * 2014-06-10 2017-04-19 3B Pharmaceuticals GmbH Conjugate comprising a neurotensin receptor ligand and use thereof
EP2954933A1 (en) * 2014-06-10 2015-12-16 3B Pharmaceuticals GmbH Conjugate comprising a neurotensin receptor ligand
WO2016146174A1 (en) 2015-03-17 2016-09-22 Biontech Ag Compositions and methods for diagnosis and treatment of cancer
CN109689115A (zh) 2016-06-10 2019-04-26 拜耳制药股份公司 放射性药物配合物
JP2018035137A (ja) 2016-07-13 2018-03-08 マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
EA202090776A1 (ru) 2017-10-23 2020-07-27 Дзе Джонс Хопкинс Юниверсити Визуализирующие и радиотерапевтические агенты, нацеленные на фибробласт-активирующий белок-альфа (fapalpha)

Also Published As

Publication number Publication date
WO2021005125A1 (en) 2021-01-14
KR20220032079A (ko) 2022-03-15
CA3145340A1 (en) 2021-01-14
AU2020310538A1 (en) 2022-01-27
CN114341159A (zh) 2022-04-12
JP2022541753A (ja) 2022-09-27
CN114341159B (zh) 2024-04-26
EP3997103A1 (en) 2022-05-18
US20220273831A1 (en) 2022-09-01
IL289675A (en) 2022-03-01
MX2022000252A (es) 2022-02-21
BR112022000122A2 (pt) 2022-04-26

Similar Documents

Publication Publication Date Title
CL2021003580A1 (es) Compuestos que comprenden un ligando de proteína de activación de fibroblastos y su uso
CL2021000704A1 (es) Anticuerpos contra proteína alfa reguladora de señal y métodos de uso. (divisional de solicitud 668-2019)
DOP2020000021A (es) Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39, y métodos de uso de anticuerpos anti-cd39
ECSP20015818A (es) Compuesto heterocíclico y su uso
ECSP18066138A (es) Inhibidores de la proteína quinasa 1 que interactua con el receptor
PH12020500398A1 (en) Antibody-pyrrolobenzodiazepine derivative conjugate
CL2022000448A1 (es) Autoinyector (divisional solicitud no. 201903061)
CL2019001554S1 (es) Automóvil.
PA8794201A1 (es) Anticuerpos anti-cxcr5 humanizados, derivados de los mismos y su uso
CL2020002540A1 (es) Anticuerpos anti-hla-g y utilización de los mismos
MX2021007274A (es) Molecula bifuncional anti-pd-1/sirpa.
BR112021020999A2 (pt) Polipeptídeos de ligação à clec12a e usos dos mesmos
BR112021004316A2 (pt) Anticorpos de agonistas anti-trem-2
CL2019002232S1 (es) Automóvil.
PH12021550289A1 (en) Ox40-binding polypeptides and uses thereof
BR112021021645A2 (pt) Anticorpos anti-hvem e uso dos mesmos.
CL2020001201S1 (es) Automóvil.
CL2020000174S1 (es) Automóvil.
UY35463A (es) Formulaciones de polipéptido fc-factor ix.
CO2019013718A2 (es) Anticuerpos anti-trkb
CL2020002459A1 (es) Variantes de anticuerpo c-terminales
BR112021013206A2 (pt) Bibliotecas de peptídeos e respectivos métodos de uso
AU201815763S (en) Quick connection coupler
CL2020000224S1 (es) Automóvil.
CL2019001482S1 (es) Lámpara de mesa.